Merz Aesthetics, a medical aesthetics business, led a Series A funding round in Acorn Biolabs, a personalized regenerative medicine company. Financial terms were not disclosed. “Merz Aesthetics is at the forefront of the emerging field of regenerative aesthetics, which seeks to stimulate the body’s own systems to repair and restore the structure and integrity of aging skin. We are looking to invest in opportunities that lie at the intersection of regenerative aesthetics and personalized medicine and our investment in Acorn Biolabs directly aligns with this strategy,” Jon Parrish, Merz Aesthetics chief corporate development officer.